Clinical trials: Tacrolimus
Lupus Nephritis
Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis
The purpose of this study is to assess the efficacy and safety of multi-target therapy in the treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ lupus nephritis.
- Trial name
- NCT00876616
- Testing
- Tacrolimus+Mycophenolate mofetil, Cyclophosphamide
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Zhi-Hong Liu, M.D.
Vernal Keratoconjunctivitis
Evaluation of the Efficacy and Safety of Tacrolimus Drops in Children With Vernal Keratoconjunctivitis
Non-interventional single-center cohort study (Rothschild Foundation Hospital) of patients aged 0 to 18 years followed up in ophthalmology for KCV, treated with tacrolimus 0.1% eye drops previously treated with ciclosporin 2%…
- Trial name
- KERAVER (NCT05076084)
- Testing
- QUICK questionnaire and 6 additional questions, Retrospective collection of clinical data from the patients' medical records
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Graft Rejection, Kidney Transplant
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
This study will look at the effect on long-term kidney function using tacrolimus right after a transplant and then switching to sirolimus at 3 to 5 months after the transplant.
- Conditions
- Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
- Trial name
- NCT00895583
- Testing
- Tacrolimus, Sirolimus
- Where
- 44 sites in United States, Argentina and 5 more
- Volunteers
- 254 people
- Sponsor
- Pfizer
Liver Transplantation
Effect of Cyclosporine A Versus Tacrolimus on Response to Antiviral Therapy After Hepatitis C Genotype -4 Recurrence Post Liver Transplantation
Background and Aim: The immunosuppression influence on the response to antiviral therapy (AVT) for recurrent hepatitis C virus (HCV) infection in liver transplant (LT) recipients remains controversial, especially for the rarely…
- Trial name
- NCT03665766
- Testing
- Cycloserine,Tacrolimus
- Volunteers
- 126 people
- Sponsor
- Ain Shams University
Dermatologic Disease
A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone
One of the most frequent skin conditions is atopic dermatitis (AD), characterized by its pruritic inflammation effect. Where the prevalence of AD increased in the last three decades by two or three folds worldwide, especially in…
- Trial name
- NCT05607901
- Testing
- Tacrolimus ointment, Hydrocortisone 1% cream
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University
Kidney Transplantation
TACrolimus in Renal Transplantation: Individualization by Pharmacogenetic
Renal transplantation is the treatment of choice of the chronic renal insufficiency arrived at its final stage. Tacrolimus is an immunosuppressant treatment used for the prevention of episodes of acute rejection.
- Trial name
- NCT00552201
- Testing
- Tacrolimus
- Where
- 10 sites in France
- Volunteers
- 280 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Kidney Transplantation, Heart Transplantation
A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation
The purpose of this study is to find out how much of Modigraf is absorbed and used in the body and how fast it leaves the body (Pharmacokinetics).
- Conditions
- Kidney Transplantation, Heart Transplantation, Liver Transplantation
- Trial name
- OPTION (NCT01371331)
- Testing
- Tacrolimus granules
- Where
- 10 sites in Belgium, France and 4 more
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Europe Ltd.
Hemochromatosis
Study of the Cellular Diffusion of Tacrolimus Across the Membrane of Mononuclear Cells
Pharmacokinetics of tacrolimus are highly variable and may result in graft rejection (underdosing) or toxicity (overdosing). The risk of transplant rejection and the toxicity of tacrolimus can be reduced by pharmacological…
- Trial name
- DIFF-TAC (NCT03654794)
- Testing
- Cell pharmacokinetics of tacrolimus
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Rennes University Hospital
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
This clinical trial evaluates the safety and effectiveness of adding itacitinib to cyclophosphamide and tacrolimus for the prevention of graft versus host disease (GVHD) in patients undergoing hematopoietic stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT05364762
- Testing
- Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Kidney Transplantation, Transplantation
Pre-transplant Assessment of Tacrolimus Blood Level Concentration, as a Predictor of Tacrolimus Dose Requirements After Kidney Transplantation
The purpose of this study is to evaluate two groups of kidney transplant recipients, to determine the proportion of patients that achieve therapeutic blood concentrations of tacrolimus by Day 3 after transplantation.
- Trial name
- NCT00297310
- Testing
- tacrolimus
- Volunteers
- 89 people
- Sponsor
- Janssen-Cilag Pty Ltd
Psoriasis Vulgaris
Botox Versus Tacrolimus in Psoriasis Vulgaris
Psoriasis is a systemic chronic relapsing immune-mediated disease which often requires a long-term therapy. Psoriasis occurs in around 2-3% of the total global population.
- Trial name
- NCT06203470
- Testing
- Botulinum Toxin-A, Tacrolimus
- Volunteers
- 60 people
- Sponsor
- Assiut University
Kidney Transplantation, Renal Transplant Recipients
Selective CD28 Blockade in Renal Transplant Recipients
The aim of this study is to evaluate the safety and efficacy of lulizumab, a CD28-specific domain antibody (CD28 dAb), compared to tacrolimus, as the primary immunosuppressant in first-time renal transplant recipients.
- Trial name
- NCT04903054
- Testing
- Lulizumab, Tacrolimus, Thymoglobulin®
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
KIDNEY TRANSPLANTATION
Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys
The purpose of this study is to explore the safety and efficacy of two different immunosuppressive regimens (sequential tacrolimus/mycophenolate mofetil [MMF] plus steroids versus tacrolimus plus MMF, following induction with…
- Trial name
- TIGRE (NCT00321113)
- Testing
- tacrolimus, mycophenolate mofetil, steroids
- Where
- 14 sites in Italy
- Volunteers
- 142 people
- Sponsor
- Astellas Pharma Inc
End-Stage Renal Disease
Study on the Safety and Efficacy of a Time-of-Day-Based Individualized Tacrolimus Dosing Regimen in Kidney Transplant Recipients
The goal of this clinical trial is to evaluate whether chronopharmacokinetic model-guided individualized unequal twice-daily tacrolimus dosing improves renal allograft function and reduces acute rejection in stable kidney…
- Trial name
- NCT07877103
- Testing
- Chronotherapy-based individualized low-morning high-evening tacrolimus dosing, conventional dosing regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Atopic Dermatitis
Protopic Adherence and Efficacy in Korean Eczema Patient
The purpose of this study is to determine whether the dosage of 0.1% tacrolimus ointment applied on unit area of eczema influence the efficacy of treatment.
- Trial name
- NCT02126176
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Pusan National University Hospital
Liver Transplant, Kidney Transplant
A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
The purpose of this study is to evaluate the impact of Advagraf, prolonged-release, once daily tacrolimus formulation, on long-term graft survival in kidney and liver allograft recipients.
- Trial name
- ADDRESS (NCT02057484)
- Testing
- Tacrolimus
- Where
- 145 sites in Austria, Belarus and 22 more
- Volunteers
- 2,300 people
- Sponsor
- Astellas Pharma Europe Ltd.
Rheumatoid Arthritis
Special Drug Use-Results Survey of Prograf Capsule in Rheumatoid Arthritis Patients
This study is to evaluate the safety and the effectiveness of treatment with tacrolimus and biological agents.
- Trial name
- NCT01870908
- Testing
- tacrolimus, biological agents
- Where
- 7 sites in Japan
- Volunteers
- 664 people
- Sponsor
- Astellas Pharma Inc
Hematologic Malignancies
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
The purpose of this study is to determine if Velcade (also known as bortezomib) can help prevent graft versus host disease (GVHD) developing after transplantation.
- Trial name
- NCT00369226
- Testing
- Bortezomib (Velcade), Tacrolimus, Methotrexate
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
End Stage Renal Disease
Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists
The purpose of this study is to evaluate the safety and efficacy of induction therapy with Thymoglobulin in comparison with IL2 receptor antagonists (daclizumab or basiliximab).
- Trial name
- NCT00859131
- Testing
- Rabbit Antithymocyte globulin, Daclizumab
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Medical University of South Carolina
Renal Transplantation
Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation
The purpose of this study is to demonstrate the efficacy and safety of voclosporin administered orally twice daily for the prevention of acute allograft rejection in recipients of a kidney transplant.
- Trial name
- INSPIRE (NCT01586845)
- Testing
- voclosporin, tacrolimus
- Sponsor
- Aurinia Pharmaceuticals Inc.